Loading...

TOVX THERIVA BIOLOGICS INC Product Launches 8-K Filing

THRV

TVX

THERIVA BIOLOGICS INC

(TOVX)

2025 8-K

Show Summary

Summary

Equity Offerings

New Product Launches

Financial Statements

Equity Offerings

Clinical Trials

Clinical Trial Update

Financial Results

FDA Meeting Outcome

Financial Results

Stock Plan Update

Orphan Drug Designation

Clinical Trial Update

Public Offering

Investor Presentations

Funding Announcement

Stock Conversion

Financial Results

FDA Designation and Stock C...

FDA Fast Track Designation ...

Conversion Notice

Financial Results

Amendment to Sales Agreement

Investor Conferences

Financial Results

Clinical Trial Continuation

Regulation FD Disclosure

Clinical Data Presentation

Presentation of Survival Ou...

Annual Meeting Results

Amendments to Bylaws

Earnings Reports

Patient Dosing Initiated in...

Announcement of FDA orphan ...

Earnings Reports

External Links:

On May 27, 2025, Theriva Biologics, Inc. announced results from a Phase 1 study of VCN-01 for retinoblastoma at the upcoming ASCO meeting, showing the treatment was well tolerated with promising antitumor activity, as eye enucleation was avoided in three patients.

AI Assistant

THERIVA BIOLOGICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.